Agenus, Inc. (AGEN)
6.87
-0.35
(-4.85%)
USD |
NASDAQ |
Nov 12, 16:00
6.81
-0.06
(-0.87%)
After-Hours: 07:42
Agenus Enterprise Value : 494.26M for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 494.26M |
| November 11, 2026 | 510.08M |
| November 10, 2026 | 501.04M |
| November 09, 2026 | 506.92M |
| November 06, 2026 | 506.92M |
| November 05, 2026 | 474.82M |
| November 04, 2026 | 498.78M |
| November 03, 2026 | 485.22M |
| November 02, 2026 | 478.89M |
| October 30, 2026 | 492.90M |
| October 29, 2026 | 504.20M |
| October 28, 2026 | 506.01M |
| October 27, 2026 | 484.31M |
| October 26, 2026 | 462.16M |
| October 23, 2026 | 469.84M |
| October 22, 2026 | 477.98M |
| October 21, 2026 | 473.01M |
| October 20, 2026 | 473.91M |
| October 19, 2026 | 463.06M |
| October 16, 2026 | 456.73M |
| October 15, 2026 | 485.67M |
| October 14, 2026 | 477.53M |
| October 13, 2026 | 497.87M |
| October 12, 2026 | 519.57M |
| October 09, 2026 | 530.42M |
| Date | Value |
|---|---|
| October 08, 2026 | 524.55M |
| October 07, 2026 | 525.90M |
| October 06, 2026 | 522.29M |
| October 05, 2026 | 578.35M |
| October 02, 2026 | 561.62M |
| October 01, 2026 | 560.26M |
| September 30, 2026 | 632.60M |
| September 29, 2026 | 686.13M |
| September 28, 2026 | 666.53M |
| September 25, 2026 | 628.60M |
| September 24, 2026 | 626.89M |
| September 23, 2026 | 622.63M |
| September 22, 2026 | 635.42M |
| September 21, 2026 | 619.65M |
| September 18, 2026 | 599.19M |
| September 17, 2026 | 572.34M |
| September 16, 2026 | 571.92M |
| September 15, 2026 | 569.79M |
| September 14, 2026 | 568.51M |
| September 11, 2026 | 560.41M |
| September 10, 2026 | 558.28M |
| September 09, 2026 | 557.00M |
| September 08, 2026 | 581.29M |
| September 04, 2026 | 615.81M |
| September 03, 2026 | 615.81M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Halozyme Therapeutics, Inc. | 13.65B |
| AVITA Medical, Inc. | 538.23M |
| Iovance Biotherapeutics, Inc. | 3.198B |
| Xencor, Inc. | 2.606B |
| Amgen, Inc. | 293.45B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.567M |
| Revenue (Quarterly) | 31.49M |
| Total Expenses (Quarterly) | 29.91M |
| EPS Diluted (Quarterly) | 0.0183 |
| Gross Profit Margin (Quarterly) | 98.37% |
| Profit Margin (Quarterly) | 4.98% |
| Earnings Yield | 10.57% |
| Operating Earnings Yield | 15.32% |
| Normalized Earnings Yield | 17.67 |